Submitted Successfully!
To reward your contribution, here is a gift for you: A free trial for our video production service.
Thank you for your contribution! You can also upload a video entry or images related to this topic.
Version Summary Created by Modification Content Size Created at Operation
1 handwiki -- 1227 2022-11-02 01:47:19

Video Upload Options

Do you have a full video?

Confirm

Are you sure to Delete?
Cite
If you have any further questions, please contact Encyclopedia Editorial Office.
HandWiki. Atypical Depression. Encyclopedia. Available online: https://encyclopedia.pub/entry/32370 (accessed on 16 October 2024).
HandWiki. Atypical Depression. Encyclopedia. Available at: https://encyclopedia.pub/entry/32370. Accessed October 16, 2024.
HandWiki. "Atypical Depression" Encyclopedia, https://encyclopedia.pub/entry/32370 (accessed October 16, 2024).
HandWiki. (2022, November 02). Atypical Depression. In Encyclopedia. https://encyclopedia.pub/entry/32370
HandWiki. "Atypical Depression." Encyclopedia. Web. 02 November, 2022.
Atypical Depression
Edit

Atypical depression as it has been known in the DSM IV, is depression that shares many of the typical symptoms of the psychiatric syndromes of major depression or dysthymia but is characterized by improved mood in response to positive events. In contrast to atypical depression, people with melancholic depression generally do not experience an improved mood in response to normally pleasurable events. Atypical depression also features significant weight gain or an increased appetite, hypersomnia, a heavy sensation in the limbs, and interpersonal rejection sensitivity that results in significant social or occupational impairment. Despite its name, "atypical" depression does not mean it is uncommon or unusual. The reason for its name is twofold: it was identified with its "unique" symptoms subsequent to the identification of melancholic depression and its responses to the two different classes of antidepressants that were available at the time were different from melancholic depression (i.e., MAOIs had clinically significant benefits for atypical depression, while tricyclics did not). Atypical depression is four times more common in females than in males. Individuals with atypical features tend to report an earlier age of onset (e.g. while in high school) of their depressive episodes, which also tend to be more chronic and only have partial remission between episodes. Younger individuals may be more likely to have atypical features, whereas older individuals may more often have episodes with melancholic features. Atypical depression has high comorbidity of anxiety disorders, carries more risk of suicidal behavior, and has distinct personality psychopathology and biological traits. Atypical depression is more common in individuals with bipolar I, bipolar II, cyclothymia and seasonal affective disorder. Depressive episodes in bipolar disorder tend to have atypical features, as does depression with seasonal patterns.

melancholic depression bipolar disorder psychopathology

1. Pathophysiology

Significant overlap between atypical and other forms of depression have been observed, though studies suggest there are differentiating factors within the various pathophysiological models of depression. In the endocrine model, evidence suggests the HPA axis is hyperactive in melancholic depression, and hypoactive in atypical depression. Atypical depression can be differentiated from melancholic depression via verbal fluency tests and psychomotor speed tests. Although both show impairment in several areas such as visuospatial memory and verbal fluency, melancholic patients tend to show more impairment than atypical depressed patients.[1]

Furthermore, regarding the inflammatory theory of depression, inflammatory blood markers (cytokines) appear to be more elevated in atypical depression when compared to non-atypical depression.[2]

2. Diagnosis

The diagnosis of atypical depression is based on the criteria stated in the Diagnostic and Statistical Manual of Mental Disorders (DSM-5). The DSM-5 defines atypical depression as a subtype of major depressive disorder that presents with "atypical features", characterized by:

  • Mood reactivity (i.e., mood brightens in response to actual or potential positive events)
  • At least two of the following:
  • Significant weight gain or increase in appetite (hyperphagia);
  • Hypersomnia (sleeping too much, as opposed to the insomnia present in melancholic depression);
  • Leaden paralysis (i.e., heavy feeling resulting in difficulty moving the arms or legs);
  • Long-standing pattern of interpersonal rejection sensitivity (not limited to episodes of mood disturbance) that results in significant social or occupational impairment.

Criteria are not met for With Melancholic Features or With Catatonic Features during the same episode.

3. Treatment

Due to the differences in clinical presentation between atypical depression and melancholic depression, studies were conducted in the 1980s and 1990s to assess the therapeutic responsiveness of the available antidepressant pharmacotherapy in this subset of patients.[3] Currently, antidepressants such as SSRIs, SNRIs, NRIs, and mirtazapine are considered the best medications to treat atypical depression due to efficacy and fewer side effects than previous treatments.[4] Bupropion, a norepinephrine reuptake inhibitor, may be uniquely suited to treat the atypical depression symptoms of lethargy and increased appetite in adults.[4] Modafinil is sometimes used successfully as an off-label treatment option.[5]

Before the year 2000, monoamine oxidase inhibitors (MAOIs) were shown to be of superior efficacy compared to other antidepressants for the treatment of atypical depression, and were used as first-line treatment for this clinical presentation. This class of medication fell in popularity with the advent of the aforementioned selective agents, due to concerns of interaction with tyramine-rich foods (such as some aged cheese, certain types of wine, tap beer and fava beans) causing a hypertensive crisis[6] and some - but not all - sympathomimetic drugs, as well as the risk of serotonin syndrome when concomitantly used with serotonin reuptake agents. Despite these concerns, they are still used in treatment-resistant cases, when other options have been exhausted, and usually show greater rates of remission compared to previous pharmacotherapies. They are also generally better tolerated by many patients.[7] There are also newer selective and reversible MAOIs, such as moclobemide, which carry a much lower risk of tyramine potentiation and have fewer interactions with other drugs.[8]

Tricyclic antidepressants (TCAs) were also used prior to the year 2000 for atypical depression, but were not as efficacious as MAOIs, and have fallen out of favor with prescribers due to the less tolerable side effects of TCAs and more adequate therapies being available.[3]

One pilot study suggested that psychotherapy such as cognitive behavioral therapy (CBT) may have equal efficacy to MAOIs for a subset of patients with atypical depression, although the sample size was small and statistical significance was not reached.[9] These are talk therapy sessions with psychiatrists to help the individual identify troubling thoughts or experiences that may affect their mental state, and develop corresponding coping mechanisms for each identified issue.[10]

No robust guidelines for the treatment of atypical depression currently exist.[11]

4. Epidemiology

True prevalence of atypical depression is difficult to determine. Several studies conducted in patients diagnosed with a depressive disorder show that about 40% exhibit atypical symptoms, with four times more instances found in female patients.[12] Research also supports that atypical depression tends to have an earlier onset, with teenagers and young adults more likely to exhibit atypical depression than older patients.[13] Patients with atypical depression have shown to have higher rates of neglect and abuse in their childhood as well as alcohol and drug disorders in their family.[1] Overall, rejection sensitivity is the most common symptom, and due to some studies forgoing this criterion, there is concern for underestimation of prevalence.[14]

5. Research

In general, atypical depression tends to cause greater functional impairment than other forms of depression. Atypical depression is a chronic syndrome that tends to begin earlier in life than other forms of depression—usually beginning in the teenage years. Similarly, patients with atypical depression are more likely to suffer from personality disorders and anxiety disorders such as borderline personality disorder, avoidant personality disorder, generalized anxiety disorder, obsessive-compulsive disorder, and bipolar disorder.[15]

Recent research suggests that young people are more likely to suffer from hypersomnia while older people are more likely to suffer from polyphagia.[16]

Medication response differs between chronic atypical depression and acute melancholic depression. Some studies suggest that the older class of antidepressants, monoamine oxidase inhibitors (MAOIs), may be more effective at treating atypical depression.[17] While the more modern SSRIs and SNRIs are usually quite effective in this illness, the tricyclic antidepressants typically are not.[15] The wakefulness-promoting agent modafinil has shown considerable effect in combating atypical depression, maintaining this effect even after discontinuation of treatment.[5] Antidepressant response can often be enhanced with supplemental medications, such as buspirone, bupropion, or aripiprazole. Psychotherapy, whether alone or in combination with medication, is also an effective treatment in individual and group settings.[18]

References

  1. Bosaipo, Nayanne Beckmann; Foss, Maria Paula; Young, Allan H.; Juruena, Mario Francisco (2017-02-01). "Neuropsychological changes in melancholic and atypical depression: A systematic review". Neuroscience & Biobehavioral Reviews 73: 309–325. doi:10.1016/j.neubiorev.2016.12.014. ISSN 0149-7634. PMID 28027956.  https://dx.doi.org/10.1016%2Fj.neubiorev.2016.12.014
  2. Łojko D, Rybakowski JK (2017). "Atypical depression: current perspectives". Neuropsychiatr Dis Treat 13: 2447–2456. doi:10.2147/NDT.S147317. PMID 29033570.  http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=5614762
  3. Stewart, Jonathan W.; Thase, Michael E. (2007-04-15). "Treating DSM-IV Depression With Atypical Features". The Journal of Clinical Psychiatry 68 (4): e10. doi:10.4088/jcp.0407e10. ISSN 0160-6689. PMID 17474800.  https://dx.doi.org/10.4088%2Fjcp.0407e10
  4. "Clinical Practice Review for Major Depressive Disorder | Anxiety and Depression Association of America, ADAA". https://adaa.org/resources-professionals/practice-guidelines-mdd. 
  5. "Modafinil for atypical depression: effects of open-label and double-blind discontinuation treatment". Journal of Clinical Psychopharmacology 26 (4): 373–8. 2006. doi:10.1097/01.jcp.0000227700.263.75.39. PMID 16855454.  https://dx.doi.org/10.1097%2F01.jcp.0000227700.263.75.39
  6. Burns, Corey; Kidron, Ariel (2021), "Biochemistry, Tyramine", StatPearls (Treasure Island (FL): StatPearls Publishing), PMID 33085344, http://www.ncbi.nlm.nih.gov/books/NBK563197/, retrieved 2021-03-10 
  7. Grady, Meghan M.; Stahl, Stephen M. (April 2012). "Practical guide for prescribing MAOIs: debunking myths and removing barriers" (in en). CNS Spectrums 17 (1): 2–10. doi:10.1017/S109285291200003X. ISSN 2165-6509. PMID 22790112. https://www.cambridge.org/core/journals/cns-spectrums/article/abs/practical-guide-for-prescribing-maois-debunking-myths-and-removing-barriers/29CA109F33F4AEC902C3CE39220AD06C. 
  8. Nair, N P; Ahmed, S K; Kin, N M (1993). "Biochemistry and pharmacology of reversible inhibitors of MAO-A agents: focus on moclobemide.". Journal of Psychiatry and Neuroscience 18 (5): 214–225. ISSN 1180-4882. PMID 7905288.  http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=1188542
  9. Mercier, MA (1992). "A pilot sequential study of cognitive therapy and pharmacotherapy of atypical depression.". The Journal of Clinical Psychiatry 53 (5): 166–70. PMID 1592844.  http://www.ncbi.nlm.nih.gov/pubmed/1592844
  10. "What is Psychotherapy?". https://www.psychiatry.org/patients-families/psychotherapy. 
  11. Łojko, Dorota (2017). "Atypical depression: current perspectives". Neuropsychiatric Disease and Treatment 13: 2447–2456. doi:10.2147/NDT.S147317. PMID 29033570.  http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=5614762
  12. Dorota Łojko, et. al (2017). "Atypical depression: current perspectives, Neuropsychiatric Disease and Treatment https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2990566/#__ffn_sectitle
  13. Tanvir Singh et. al (2006). "Atypical depression, Psychiatry (Edgmont). https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2990566/#!po=65.7895
  14. Quitkin FM (2002). "Depression With Atypical Features: Diagnostic Validity, Prevalence, and Treatment". Prim Care Companion J Clin Psychiatry 4 (3): 94–99. doi:10.4088/pcc.v04n0302. PMID 15014736.  http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=181236
  15. American Psychiatric Association. (2000). Mood Disorders. In Diagnostic and Statistical Manual of Mental Disorders (4th ed., text rev.) Washington, DC: Author.
  16. "Symptoms of atypical depression". Psychiatry Research 104 (2): 175–81. 2001. doi:10.1016/S0165-1781(01)00301-8. PMID 11711170.  https://dx.doi.org/10.1016%2FS0165-1781%2801%2900301-8
  17. "Atypical depression - Symptoms and Causes". Mayo Clinic. https://www.mayoclinic.org/diseases-conditions/atypical-depression/symptoms-causes/syc-20369747. 
  18. Hunsley, J., Elliott, K., & Therrien, Z. (2014). The efficacy and effectiveness of psychological treatments for mood, anxiety, and related disorders. Canadian Psychology/Psychologie canadienne, 55(3), 161–176. https://doi.org/10.1037/a0036933
More
Information
Subjects: Others
Contributor MDPI registered users' name will be linked to their SciProfiles pages. To register with us, please refer to https://encyclopedia.pub/register :
View Times: 713
Entry Collection: HandWiki
Revision: 1 time (View History)
Update Date: 02 Nov 2022
1000/1000
ScholarVision Creations